AstraZeneca’s new cholesterol pill is showing promise, while the FTC urged a potential buyer of 23andMe to protect user data.

Johnson & Johnson has pulled ahead of rival AstraZeneca Plc in a race to dominate the blockbuster market for lung cancer treatment, but data from a forthcoming study could quickly shake up the ...

The trial will include patients with locally advanced or metastatic HER2-positive, PD-L1-positive gastric or gastroesophageal junction cancer.

Imfinzi was generally well tolerated, and no new safety signals were observed in the neoadjuvant and adjuvant settings.

NEW YORK – The UK's National Institute for Health and Care Excellence (NICE) on Friday recommended that the National Health Service make AstraZeneca's AKT pathway inhibitor Truqap (capivasertib) with ...

The Eater New York Heatmap has existed for nearly two decades to answer the age-old question: “What’s hot and new in Manhattan?” Eater editors do thorough reporting on the most exciting ...

Approval of Imfinzi marks the first and only perioperative immunotherapy indicated for muscle-invasive bladder cancer.

AstraZeneca’s Imfinzi receives US FDA approval for patients with muscle-invasive bladder cancer: Cambridge, UK Tuesday, April 1, 2025, 10:00 Hrs [IST] AstraZeneca’s Imfinzi (d ...

Stocks like Indian Bank, Tata Motors, ITC, Puravankara, Federal Bank, Bajel Projects, TVS Motor Company, Biocon, Force Motors ...